Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
International Journal of Surgical Pathology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Panizo-Santos, A.
Right arrow Articles by Pardo-Mindín, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Panizo-Santos, A.
Right arrow Articles by Pardo-Mindín, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Predicting Metastatic Risk of Gastrointestinal Stromal Tumors: Role of Cell Proliferation and Cell Cycle Regulatory Proteins

Angel Panizo-Santos, MD, PhD

Iosu Sola, MD, PhD

Francisco Vega, MD

Enrique De Alava, MD, PhD

María Dolores Lozano, MD, PhD

Miguel Angel Idoate, MD, PhD

Javier Pardo-Mindín, MD, PhD

Departamento de Anatomía Patológica, Clínica Universitaria, de Navarra, Pamplona, Navarra, Spain

Gastrointestinal stromal tumors (GIST) are a heterogeneous group of neoplasms whose biologic behavior is difficult to predict. The aim of this study is to evaluate the prognostic value in GIST of some oncoproteins involved in regulation of cell proliferation. Tumor size, mitosis, necrosis, and p53, c-myc, and bcl-2 protein expression of 32 GIST were studied. Proliferative index was assessed with Ki67. The 32 cases were grouped into the following clinical categories: (1) clinically benign (BN) were defined as disease-free survival greater than 3 years (n=10); (2) clinically malignant (MN) in which local recurrence or metastasis occurred regardless of the follow-up time (n=1 5); and (3) clinically indeterminate (ID) owing to follow-up <3 years without metastasis or local recurrence (n=seven). Discriminant analysis was used to allocate any tumor to one of the two prognostic groups (BN or MN). In univariate analysis all six factors studied above proved to be of significant prognostic value. Using a multivariate stepwise discriminant analysis to take into account the interrelationship between factors, we found that c-myc expression was the most important prognostic factor, followed, in order of statistical weight, by size and Ki67. These were combined to define a discriminant score ([10.75 x c-myc]+[0.39 x size]+[0.078 x Ki67]-15.54=score), which was capable of correctly identifying tumors in our series whose known clinical behavior was BN or MN in 92% of the cases. The classification score was applied subsequently to the seven clinically ID cases: Three (42.9%) were predicted as BN, and four (57.1%) were predicted as MN. Both expression of oncoprotein c-myc and the proliferative index provide prognostic information in GIST, in addition to morphologically established prognostic factors such as size. These factors in a discriminant analysis proved to be useful for the clinical classification of GIST into BN or MN and to predict the clinical outcome of clinically ID tumors.

Key Words: gastrointestinal stromal tumors • oncoproteins • immunohistochemistry • prognosis

International Journal of Surgical Pathology, Vol. 8, No. 2, 133-144 (2000)
DOI: 10.1177/106689690000800208


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Romeo, M. Debiec-Rychter, M. Van Glabbeke, H. Van Paassen, P. Comite, R. Van Eijk, J. Oosting, J. Verweij, P. Terrier, U. Schneider, et al.
Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors
Clin. Cancer Res., June 15, 2009; 15(12): 4191 - 4198.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
S. L. Blair, W. B. Al-Refaie, J. Wang-Rodriguez, C. Behling, M.-W. Ali, and A. R. Moossa
Gastrointestinal Stromal Tumors Express ras Oncogene: A Potential Role for Diagnosis and Treatment
Arch Surg, June 1, 2005; 140(6): 543 - 548.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
T. Gelen, G. O. Elpek, N. H. Aksoy, M. Ogus, and N. Keles
p27 Labeling Index and Proliferation in Gastrointestinal Stromal Tumors: Correlations with Clinicopathologic Factors and Recurrence
Jpn. J. Clin. Oncol., July 1, 2003; 33(7): 346 - 352.
[Abstract] [Full Text] [PDF]


Home page
INT J SURG PATHOLHome page
J. Rosai
GIST: An Update
International Journal of Surgical Pathology, July 1, 2003; 11(3): 177 - 186.
[PDF]


Home page
JCOHome page
R. Schneider-Stock, C. Boltze, J. Lasota, M. Miettinen, B. Peters, M. Pross, A. Roessner, and T. Gunther
High Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors
J. Clin. Oncol., May 1, 2003; 21(9): 1688 - 1697.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W.Y. Au, W.M. Wong, U.S. Khoo, and R. Liang
Challenging and Unusual Cases: CASE 2. CONCURRENT GASTROINTESTINAL STROMAL TUMOR AND BURKITT'S LYMPHOMA
J. Clin. Oncol., April 1, 2003; 21(7): 1417 - 1418.
[Full Text] [PDF]


Home page
JCOHome page
S. Singer, B. P. Rubin, M. L. Lux, C.-J. Chen, G. D. Demetri, C. D.M. Fletcher, and J. A. Fletcher
Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors
J. Clin. Oncol., September 15, 2002; 20(18): 3898 - 3905.
[Abstract] [Full Text] [PDF]